Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01573572 · ClinicalTrials.gov registry record · Phase 4
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
A Phase 4 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 4
- Development phase
- 131
- Enrollment target
NCT01573572 is a Phase 4 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 131 participants.
The verdict
NCT01573572, a Phase 4 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 131 participants
- Enrollment target
Study Summary
This study was conducted because the FDA requested clinical information on potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium from a 1-year (minimum) post-approval clinical study to support that there are no adverse effects on the corneal endothelium following intravitreal injections of Macugen.
Interventions
- DRUG pegaptanib sodium injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2010-04-22 |
| Est. Completion | 2019-11-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01573572
The ClinicalTrials.gov registry entry for NCT01573572 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pegaptanib sodium injection is the first listed.
NCT01573572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01573572 about?
NCT01573572 is a clinical study titled "Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium". This study was conducted because the FDA requested clinical information on potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium from a 1-year (minimum) post-approval clinical study to support that there are no adverse effects on the corneal...
What is the current status of trial NCT01573572?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 131 participants. The study started on 2010-04-22. Estimated completion is 2019-11-14.
What interventions are being tested in trial NCT01573572?
The interventions under investigation include: pegaptanib sodium injection (DRUG).
Who is sponsoring clinical trial NCT01573572?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.